Review
Fluorescence in Situ Hybridization Study of HER-2/neu Oncogene Amplification in Prostate Cancer

https://doi.org/10.1006/exmp.1999.2242Get rights and content

Abstract

Prostate cancer is a serious disease affecting men worldwide and treatment compromises the quality of life of prostate cancer patients. We conducted a study of 88 cases of prostate cancer in an attempt to identify prognostic biomarkers that can distinguish aggressive cases that must be treated immediately. HER-2/neu oncogene amplification was initially studied because amplification of this gene has been reported in many other cancers, including those studied in this laboratory. Fluorescence in situ hybridization (FISH) using a HER-2/neu gene probe with a chromosome 17 centromere control probe was performed on formalin-fixed, paraffin-embedded tissues. Of a total of 86 cases successfully analyzed, only 8 (9.3%) were found to be amplified. This frequency was lower than the frequency of amplification found in other cancers studied. Furthermore, no case was found where the level of amplification can be considered high. Only one case was found to have moderate amplification. The rest of the positive cases can all be classified as low amplification. Thus, while we have demonstrated that FISH is a sensitive technique for detecting oncogene amplification, the frequency and level of HER-2/neu amplification detected in prostate cancer seem to be lower than those in most cancers that we studied. In view of the fact that HER-2/neu amplification does not seem to play as significant a role, exploration of other biomarkers in prostate cancer is warranted.

References (32)

  • K.I. Bland et al.

    Oncogene protein co-expression: Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma

    Ann. Surg.

    (1995)
  • H.B. Carter et al.

    Diagnosis and staging of prostate cancer

  • G.M. Clark et al.

    Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry

    N. Engl. J. Med.

    (1989)
  • M.J. Costa et al.

    C-erb B-2 oncogene overexpression in uterine cervix carcinoma with glandular differentiation

    Am. J. Clin. Pathol.

    (1995)
  • G. Fournier et al.

    Gene amplification in advanced-stage human prostate cancer

    Urol. Res.

    (1995)
  • Cited by (51)

    • Matriptase is involved in ErbB-2-induced prostate cancer cell invasion

      2010, American Journal of Pathology
      Citation Excerpt :

      A similar result was also found by Osman et al.6 Together, this suggests that the protein level of ErbB-2 could be elevated in a subgroup of recurrent, hormone-refractory prostate cancer. In prostate tumor tissue, the results from the chromogenic in situ hybridization showed that ErbB-2 gene is not amplified, as reported by several groups.8,63–66 Thus, it is clear that ErbB-2 gene is not amplified in prostate carcinomas although the protein level may be elevated in a subgroup of patients, especially with metastasis.6,8

    • Molecular markers of prostate cancer outcome

      2005, European Journal of Cancer
    • Genetic alterations in prostate cancer

      2005, Clinical Prostate Cancer
    View all citing articles on Scopus

    We thank Dr. Roger Mark for reading the manuscript. The support of the staff at the Lifespan Academic Medical Center Cytogenetics Laboratory is also acknowledged. This project was supported in part by Vysis (Downers Grove, IL).

    View full text